A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

Dirk Blom; Tomas Hala; Michael A. Bolognese; Michael Lillestol; Phillip D. Toth; Lesley Burgess; R Češka; Eli M. Roth; Michael J. Koren; Christie M. Ballantyne; Maria Laura Monsalvo; Kate Tsirtsonis; Jae Bum Kim; Robert C. Scott; Scott M. Wasserman; Evan A. Stein

doi:10.1056/nejmoa1316222

Abstract

At 52 weeks, evolocumab added to diet alone, to low-dose atorvastatin, or to high-dose atorvastatin with or without ezetimibe significantly reduced LDL cholesterol levels in patients with a range of cardiovascular risks. (Funded by Amgen; DESCARTES ClinicalTrials.gov number, NCT01516879.).

Keywords

EvolocumabMedicinePCSK9PlaceboAtorvastatinHyperlipidemiaEzetimibeInternal medicineCholesterolClinical endpointEndocrinologyGastroenterologyUrologyRandomized controlled trialLipoproteinDiabetes mellitus

Affiliated Institutions

Related Publications

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR**STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)

Peter H. Jones , Michael H. Davidson , Evan A. Stein +5 more

The primary objective of this 6-week, parallel-group, open-label, randomized, multicenter trial was to compare rosuvastatin with atorvastatin, pravastatin, and simvastatin acros...

2003 The American Journal of Cardiology 1382 citations

Treating to New Targets (TNT) Study: does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?

David D. Waters , John R. Guyton , David M. Herrington +3 more

The Treating to New Targets (TNT) trial is a parallel-group study that has randomized 10,003 patients from 14 countries to double-blind treatment with either atorvastatin 10 or ...

2004 The American Journal of Cardiology 198 citations

Comparison of Once-Daily, niacin Extended-Release/lovastatin with standard doses of atorvastatin and simvastatin (the advicor versus other Cholesterol-Modulating agents trial evaluation [ADVOCATE])

Harold Bays , Carlos A. Dujovne , Mark E. McGovern +4 more

This study compared the relative efficacy of a once-daily niacin extended-release (ER)/lovastatin fixed-dose combination with standard doses of atorvastatin or simvastatin, with...

2003 The American Journal of Cardiology 153 citations

Once‐daily pravastatin in patients with primary hypercholesterolemia: A dose‐response study

Peter H. Jones , John A. Farmer , Michael D. Cressman +12 more

Abstract This multicenter, double‐blind, placebo‐controlled study was conducted to evaluate dose‐response effects and safety of once‐daily administration of pravastatin, a new i...

1991 Clinical Cardiology 65 citations

Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT

Erin A. Bohula , Robert P. Giugliano , Christopher P. Cannon +6 more

Background— Statins lower low-density lipoprotein cholesterol (LDL-C) and high-sensitivity C-reactive protein (hs-CRP); addition of ezetimibe to statins further reduces LDL-C an...

2015 Circulation 327 citations

Publication Info

Year: 2014
Type: article
Volume: 370
Issue: 19
Pages: 1809-1819
Citations: 697
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

697

OpenAlex

Cite This

APA Style

                            
                                
                                    Dirk Blom, 
                                
                                    Tomas Hala, 
                                
                                    Michael A. Bolognese
                                
                                et al.
                            
                            (2014). 
                            A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia. 
                            New England Journal of Medicine
                            , 370
                            (19)
                            , 1809-1819.
                            https://doi.org/10.1056/nejmoa1316222
                        

Identifiers

DOI: 10.1056/nejmoa1316222